Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

The FDA last week approved Eli Lilly’s Mounjaro injection for the treatment of type 2 diabetes. The drug is the first GIP and GLP-1 receptor agonist in the diabetes market basket, and can also treat obesity. In a 2021 study, Mounjaro beat out Novo Nordisk’s top-selling Ozempic in patients’ blood sugar levels and overall weight loss. For the treatment of diabetes, Ozempic holds covered or better status for 97% of all insured lives under the pharmacy benefit. 40.5% of covered lives have preferred access to Ozempic without utilization management restrictions. As a treatment for obesity, Ozempic is marketed as Wegovy, and holds covered or better status for 49% of all insured lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 5/18/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today